Bringing the very best science and medicine to our best equine friends

NEWS

Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotion Pathology

San Francisco, CA (March 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is proud to announce its partnership with the International Society of Equine Locomotion Pathology (ISELP) by joining their team of Global Sponsors starting in 2017. The partnership with ISELP is part of an initiative by KindredBio to support the education of veterinarians and veterinary students, and to promote the growth and advancement of the equine industry. ISELP is an advanced education program for equine veterinarians to learn the most advanced techniques in diagnostics and treatments for the …

Continue Reading

Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results

San Francisco, CA (March 1, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016. “We are very pleased with the progress of Mirataz™ and Zimeta™, including the recently announced approval of the efficacy technical section for Mirataz,” stated Richard Chin, M.D., President and CEO of KindredBio. “We are looking forward to the transition to a commercial-stage company in 2017, with the anticipated approval and launch of two products in the second half of the year, …

Continue Reading

Kindred Biosciences to Announce Fourth Quarter and Year-End 2016 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 1, 2017 San Francisco, CA (February 21, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2016 financial results on March 1, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, …

Continue Reading

Kindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz New Animal Drug Application

San Francisco, CA (February 6, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced it has received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine for Mirataz™ (mirtazapine transdermal ointment) approving the technical section. The basis for this complete letter was a multicenter, randomized, double-blind, placebo-controlled pivotal field study that enrolled 230 cats to assess the effectiveness of Mirataz in managing weight loss in cats. The primary endpoint was mean percentage change in body weight from Day 1 to Week …

Continue Reading

Kindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine Practitioners Convention

San Francisco, CA (November 29, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Emily Sundman, DVM, Clinical Development Scientist for KindredBio, will present pivotal effectiveness data for Zimeta™ (dipyrone injection) at the American Association of Equine Practitioners (AAEP) Convention in Orlando, FL on Tuesday, December 6, 2016 at 8:25 AM ET as part of the Internal Medicine track. The presentation will be available at http://kindredbio.com/investor-relations/events/ following the AAEP presentation. Zimeta is a pyrazolone anti-inflammatory drug with a unique mechanism of action that is under development for the …

Continue Reading

Kindred Biosciences to Present at 9th Annual LD Micro Investor Conference

San Francisco, CA (November 18, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, President and CEO, will be presenting at the 9th Annual LD Micro Investor Conference in Los Angeles, CA on Wednesday, December 7, 2016 at 1:30 PM PT. The conference is being held at the Luxe Sunset Boulevard Hotel. The presentation will be available via a live webcast at the following URL: http://wsw.com/webcast/ldmicro11/kin. An archived version of the webcast and presentation will be available for 30 days on the Company’s website: http://kindredbio.com/investor-relations/events. About …

Continue Reading

Kindred Biosciences Announces Third Quarter 2016 Financial Results

San Francisco, CA (November 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2016 and provided updates on its programs. “We are pleased with the progress across our programs as we execute our strategy of quickly and cost-effectively developing therapeutics for our animal family members. In support of the anticipated launch of Zimeta™ (dipyrone injection) and Mirataz™ (mirtazapine 2% ointment), we have been hiring key personnel, building our veterinary technical services and establishing distribution channels. The advances of our …

Continue Reading